Please login to the form below

Not currently logged in
Email:
Password:

NICE backs Sanofi's Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Kevzara

Sanofi is celebrating a positive recommendation from the UK’s cost effectiveness watchdog for its rheumatoid arthritis (RA) treatment Kevzara (sarilumab).

Given in combination with methotrexate, the drug maker’s IL-6 inhibitor will be made available for routine use under the NHS for adults with severe RA who have responded inadequately to disease modifying anti-rheumatic drugs (DMARDs).

Peter Kuiper, Sanofi Genzyme’s general manager for UK and Ireland, said: “This recommendation brings us one step closer to making Kevzara available to adult patients with severe RA and reinforces Sanofi’s on-going commitment to helping people impacted by often complex, misunderstood and debilitating diseases.”

According to Arthritis Research UK, more than 400,000 people in the UK have RA, and the disease increases patients’ risk of cardiovascular problems, infections and certain cancers.

Professor Ernest Choy, consultant rheumatologist, University of Cardiff, said: “Rheumatoid arthritis is an unpredictable chronic disease, which can strike at any age, often causing severe pain and comorbidities, which can have a huge impact on all aspects of daily life, including psychological wellbeing.”

NICE’s final appraisal determination was based on the MONARCH study, which demonstrated that sarilumab reduced signs and symptoms experienced by people with RA and improved physical function compared with another biological therapy.

The product - which was developed jointly by Sanofi and Regeneron - was granted EU marketing authorisation for the same indication back in June 2017, but now can be made available for use in England and Wales, UK.

Article by
Gemma Jones

2nd October 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Harnessing the power of core elements to optimise market access
This article by John Spoors and Anton Abrahams focuses on optimising market access – the RJW and Solaris Health teams operate across all major markets, where the principles set out...
So how do you really engage with patients?
The most valuable insights from patient engagement are the most unexpected ones. Simple things, which may seem unimportant to you, may be the key to making patients’ lives easier and...
data
Avoiding data pitfalls in clinical research
Genomics sequencing and sensors will present new challenges...

Infographics